key: cord-0311457-6sr2frf1 authors: Calarco, S.; Fernandez-Carballo, B. L.; Keller, T.; Weber, S.; Jakobi, M.; Marsall, P.; Schneiderhan-Marra, N.; Dittrich, S. title: Analytical performance of 17 commercially available point-of-care tests for CRP to support patient management at lower levels of the health system date: 2022-04-27 journal: nan DOI: 10.1101/2022.04.23.22273766 sha: 6586ee57eb147f40f68ba7bddffec70e8544b4bc doc_id: 311457 cord_uid: 6sr2frf1 Accurate and precise point-of-care (POC) testing for C-reactive protein (CRP) can help support healthcare providers in the clinical management of patients. Here, we compared the analytical performance of 17 commercially available POC CRP tests to enable more decentralized use of the tool. The following CRP tests were evaluated. Eight quantitative tests: QuikRead go (Aidian), INCLIX (Sugentech), Spinit (Biosurfit), LS4000 (Lansionbio), GS 1200 (Gensure Biotech), Standard F200 (SD Biosensor), Epithod 616 (DxGen), IFP-3000 (Xincheng Biological); and nine semi-quantitative tests: Actim CRP (ACTIM), NADAL Dipstick (nal von minden), NADAL cassette (nal von minden), ALLTEST Dipstick (Hangzhou Alltest Biotech), ALLTEST Cassette cut-off 10-40-80 (Hangzhou Alltest Biotech), ALLTEST Cassette cut-off 10-30 (Hangzhou Alltest Biotech), Biotest (Hangzhou Biotest Biotech), BTNX Quad Line (BTNX), BTNX Tri Line (BTNX). Stored samples (n=660) had previously been tested for CRP using Cobas 8000 Modular analyzer (Roche Diagnostics International AG, Rotkreuz, Switzerland ((reference standards). CRP values represented the clinically relevant range (10-100 mg/L) and were grouped into four categories (<10 mg/L, 10-40 mg/L or 10-30 mg/L, 40-80 mg/L or 30-80 mg/L, and > 80mg/L) for the semi-quantitative tests. Among the eight quantitative POC tests evaluated, QuikRead go and Spinit exhibited better agreement with the reference method, showing slopes of 0.963 and 0.921, respectively. Semi-quantitative tests with the four categories showed a poor percentage agreement for the intermediate categories and higher percentage agreement for the lower and upper limit categories. Analytical performance varied considerably for the semi-quantitative tests, especially among the different categories of CRP values. Our findings suggest that quantitative tests might represent the best choice for a variety of use cases, as they can be used across a broad range of CRP categories. . Whether the test was CE-marked, relevant detection range (from 10 to 100 mg/L CRP for a quantitative 122 test, and one cut-off value of ≥20 mg/L for qualitative and semi-quantitative tests), worldwide distribution, 123 and responsiveness of the manufacturer. Ranking criteria included: Additional regulatory certification 124 (higher score for US Food and Drug Administration-approved products); cost of consumables (lower score 125 for test price >10 USD, higher score for test price <1 USD); assay sample type (lower score for tests 126 requiring serum samples only, higher score for tests that can be used with capillary whole blood, venous 127 blood, or plasma); sample volume (lower score for tests requiring a volume of >50 µL, higher score for tests 128 requiring a volume of <10 µL); time to result (lower score for tests requiring >20 min, higher score for tests 129 requiring <5 min); storage temperature (lower score for tests requiring <4°C, higher score for tests stable 130 up to 40°C); shelf-life (lower score for tests stable for <12 months, higher score for tests stable for >24 131 months). 132 Table 1 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2022. , PG I and PG II, TT3, COVID-19 antigen Yes PCT, SAA, IL-6, HBP, TNF α, Fungal 1,3 β-D glucan, cTn I, NT-proBNP, BNP, cTnI/Myo/CK-MB, HFABP, D-D, MPO, Lp-PLA2, ST2, S100-β, IGFBP-1, PLGF, β -HCG, FSH, LH, PROG, TES, HGH, AMH, INH B, PRL, E2, VB12, FA, 25-OH-VD, SF, TRF, BGP, PTH, PG I, PG II, GP-17, NGAL, Cys C, β2-MG, RBP, MAU, T3, T4, TSH, TG is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2022. 165 guidelines EP9 allow separate concentration ranges to be analyzed. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 232 The BA plots were applied to ranges with a homogeneous distribution of differences. The 233 bias, along with its 90% CI, was estimated using the means of duplicate measurements. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22273766 doi: medRxiv preprint 274 Our search identified 56 tests, which were then assessed according to the predefined 275 criteria (Fig 1) . Following this assessment, 17 tests (8 quantitative and 9 semi-276 quantitative) from 13 companies were included in the study (Table 1) . Equivalence of reference methods 278 We were able to confirm equivalence (using TOSTs, with acceptance criteria +/-8%) for Table 2) . For three devices 291 (QuikRead go, Spinit, and INCLIX), an acceptable agreement with the reference method 292 was seen. For the PB regression analysis (Fig 2) , the slope was in the 0.91-1.1 range 293 (meaning +/-10%) for QuikRead go and Spinit. In the BA plot analysis (Fig 3) , the mean 294 bias was -1.2 (90% CI: -4.7 to 2.3%) and -7.5% (90% CI: 9.3-5.7%) for INCLIX and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22273766 doi: medRxiv preprint 295 QuikRead go, respectively. The regression analysis (Fig 2) showed that an 296 overestimation of CRP values occurred with STANDARD F 200, EPITHOD 616, and IFP-297 3000 when compared with the reference method. 298 Overall, QuikRead go and Spinit (and, to a lesser extent, INCLIX and GS 1200) showed 299 best agreement with the reference method (Fig 2) . 300 301 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22273766 doi: medRxiv preprint 307 analysis because the values were (for PB and BA) outside the AR or (for BA) violated the assumption of 308 homogeneity of variances (mean <3 mg/L, IFP 3000). 309 *Spinit and QuikRead go showed the best slope and intercept, near to 1 and 0, respectively. 310 NB: One outlier found with both replicates was excluded for LS4000. For EPITHOD 616 and GS1200, 311 strong deviating replicates were found for one sample in both cases, so a third measurement was then 312 performed and the pair with similar values was chosen for analysis. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (Fig 4) , used for analysis visualization, also showed a 353 greater agreement among all the categories for the NADAL cassette and BTNX Quad 354 Line tests. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22273766 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22273766 doi: medRxiv preprint Kappa (simple, linear weighted) and percentage agreement within specific ranges of the reference method, 368 according to the cut-off of the investigated method. Within equal cut-off groups *Semi-quantitative tests (BTNX CRP quad line and NADAL cassette) showed a good agreement Y-axis: categories using 374 measurement values of the reference method, X-axis: categories according to the different index tests (units 375 are mg/L). The horizontal width refers to the number of measurement results in the category. The gray 376 shading refers to varying degrees of agreement (darker gray = a better degree of agreement). Overall, a 377 good agreement is indicated by a square shape, with corners on the diagonal identity line and a large samples. Overall, the quantitative tests showed a satisfactory performance For most of the semi-quantitative tests, the percentage of agreement with the reference 428 method varied according to the CRP-level category being examined. Notably, tests with 429 three test bands (the equivalent of four categories) showed a lower percentage of 430 agreement for the 10-40 and 40-80 mg/L categories (from 7% to 83%) For BTNX Tri Line, on the contrary, a high percentage 433 agreement was observed for the intermediate categories 10-30 and 30-80 mg/L (86 % 434 and 80% respectively), while the category > 80 mg/L showed only 27% of agreement The current results highlight that, depending on the relevant CRP cut-off needed for the 436 clinical use-case, the utility of the different tests may vary The (binary) diagnostic accuracy for CRP-measurements at a cut-off 10 mg/L was also 438 explored, as this is a common cut-off used, across tests and use cases, like tuberculosis 439 and pneumonia Although we aimed to follow the standardized procedures as outlined by the CLSI there were some limitations to our study. Two different reference methods were 463 used (C-reactive protein high sensitive ELISA from IBL International and Cobas 8000 Modular analyzer from Roche Diagnostics International AG), but we could confirm In summary, we set out to provide pragmatic data to users, procurement agencies, 471 laboratories, implementers, and ministries of health Usefulness of C-reactive protein testing in acute cough / 486 respiratory tract infection : an open cluster-randomized clinical trial with C-reactive 487 protein testing in the intervention group 489 Antibiotic prescription practices in primary care in low-And middle-income 490 countries: A systematic review and meta-analysis The value of biochemical 492 markers in predicting a perforation in acute appendicitis Point-of-care testing with CRP in 494 primary care : a registry-based observational study from Norway Diagnosis and management of community and hospital 497 acquired pneumonia in adults : summary of NICE Diagnostic value of 499 inflammation markers in predicting perforation in acute sigmoid diverticulitis. World 500 J Surg Predictive value of C-reactive 502 protein at different cutoff levels in acute appendicitis Precision of C-reactive protein in the 505 diagnosis of acute appendicitis Host Biomarkers for Distinguishing 507 Bacterial from Non-Bacterial Causes of Acute Febrile Illness : A Comprehensive 508 Review Reactive Protein Levels as Markers of Bacterial Infection : A Systematic Review 511 and Meta-analysis Protein Levels 513 Predict Bacterial Exacerbation in Patients With Chronic Obstructive Pulmonary 514 Disease C-reactive protein in viral and bacterial respiratory infection in 516 children Anticipating the future: 521 prognostic tools as a complementary strategy to improve care for patients with 522 febrile illnesses in resource-limited settings Target product profile for a diagnostic assay to 526 differentiate between bacterial and non-bacterial infections and reduce 527 antimicrobial overuse in resource-limited settings: An expert consensus Global burden of bacterial antimicrobial resistance in 2019 : a 530 systematic analysis Antimicrobial resistance: Risk associated with antibiotic overuse 532 and initiatives to reduce the problem Evidence of 534 antibiotic resistance from population-based studies: A narrative review Module 2: screening -systematic 537 screening for tuberculosis disease. Geneva: World Health Organization 540 Evaluation of the diagnostic performance of laboratory-based c-reactive protein as 541 a triage test for active pulmonary tuberculosis Derivation of performance specifications for uncertainty of 543 serum C-reactive protein measurement according to the Milan model 3 (state of the 544 art) The European Commission. Regulation (EU) 2017/746 of the European parliament 546 and of the council on in vitro diagnostic medical devices Desirable Specifications for Total Error , Imprecision , and Bias , derived from Intra-549 and Inter-Individual Biologic Variation Analytical performance, 552 agreement and user-friendliness of five C-reactive protein point-of-care tests Validation and evaluation of eight commercially available 555 point of care CRP methods C-reactive protein cut-offs used for acute 557 respiratory infections in Danish general practice Bacterial versus non-bacterial infections: A methodology to support use-561 case-driven product development of diagnostics Measurement Procedure Comparison and Bias Estimation Using Patient 564 Samples; Approved Guideline-Third Edition. CLSI Doc EP09-A3 Wayne, PA Clin 565 Lab Stand Institute The measurement of observer agreement for categorical 567 data Practical statistics for medical research Ein neues biometrisches Verfahren zur Überprüfung der Gleichheit von 571 Meßwerten von zwei analytischen Methoden: Anwendung von linearen 572 Regressionsverfahren bei Methodenvergleichsstudien in der Klinischen Chemie Statistical methods for assessing agreement between 575 two methods of clinical measurement An overview on assessing agreement with 577 continuous measurements The agreement chart User Protocol for Evaluation of Qualitative Test Performance EP9-A2 Method Comparison and Bias 585 Estimation Using Patient Samples Distinctive biochemical changes in pulmonary tuberculosis and 587 pneumonia Performance of Serum C-Reactive Protein as a 589 Screening Test for Smear-Negative Tuberculosis in an Ambulatory High HIV 590 Prevalence Population The selection and use of essential in vitro diagnostics: report of the third meeting 592 of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2020 593 (including the third WHO model list of essential in vitro diagnostics). Geneva: World 594 Health Organization Biomarkers for acute febrile illness at the point-of-care il low-resource settings 480 The authors wish to thank the participants who provided the samples and Adam Bodley 481 for medical writing assistance and the editorial support.